Gene-knocked out chimeric antigen receptor (CAR) T cells: Tuning up for the next generation cancer immunotherapy.

Recently clinical trials utilizing genetically engineered T cells expressing a chimeric antigen receptor (CAR) that is half monoclonal antibody and half T-cell receptor have demonstrated remarkable response in patients with advanced cancers like relapsed or refractory acute lymphoblastic leukemia (ALL) and lymphoma. Moreover, emerging chimeric genome editing tools such as zinc-finger nucleases (ZNFs), transcription activator-like effector nucleases (TALENs) and clustered regulatory interspaced short palindromic repeat (CRISPR)/Cas composed of sequence-specific DNA binding module(s) linked to a non-specific DNA cleavage domain have made possible to dramatically expand the ability to manipulate cells aim to treat and/or study a wide range of diseases including cancer. Here, we will discuss how joint application of these two chimeras will help us to manipulate CAR T cells aiming to enhance the efficacy of CAR T cell therapy in preclinical and clinical settings.

• Publication year

  2018

• Venue

  Cancer Letters

• Publication date

  2018-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.canlet.2018.03.010PMID 29544719
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The multiplexed CRISPR targeting platforms.

  2018cited by this paper
• Mesenchymal stem cells: A new platform for targeting suicide genes in cancer

  2018cited by this paper
• The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model.

  2018cited by this paper
• Use of gene-editing technology to introduce targeted modifications in pigs

  2018cited by this paper
• Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis

  2018cited by this paper
• Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor–Modified T Cells Engineered to Secrete Checkpoint Inhibitors

  2017cited by this paper
• PARP-1/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas

  2017cited by this paper
• Refining strategies to translate genome editing to the clinic

  2017cited by this paper
• TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance

  2017cited by this paper
• Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells

  2017cited by this paper
• Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications

  2017cited by this paper
• Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

  2017cited by this paper
• CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles

  2016cited by this paper
• Boron neutron capture therapy: Moving toward targeted cancer therapy.

  2016cited by this paper
• Synthetic human genome set to spur applications

  2016cited by this paper
• CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients

  2016cited by this paper
• Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

  2016cited by this paper
• CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

  2016cited by this paper
• Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents.

  2016cited by this paper
• Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.

  2016cited by this paper
• Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

  2016cited by this paper
• Mesenchymal stem cell: a new horizon in cancer gene therapy

  2016cited by this paper
• First-in-human CRISPR trial

  2016cited by this paper
• Genome engineering: NHEJ and CRISPR–Cas9 improve gene therapy

  2016cited by this paper
• Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

  2016cited by this paper
• Lack of p53 Augments Antitumor Functions in Cytolytic T Cells.

  2016cited by this paper
• Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.

  2016cited by this paper
• SiRNA and epigenetic aberrations in ovarian cancer.

  2016cited by this paper
• Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.

  2015cited by this paper
• Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN.

  2015cited by this paper
• CD4+ T cells apoptosis in Plasmodium vivax infection is mediated by activation of both intrinsic and extrinsic pathways

  2015cited by this paper
• Proteasome-Mediated Reduction in Proapoptotic Molecule Bim Renders CD4+CD28null T Cells Resistant to Apoptosis in Acute Coronary Syndrome

  2015cited by this paper
• Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia

  2015cited by this paper
• A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy

  2015cited by this paper
• Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.

  2015cited by this paper
• Tax contributes apoptosis resistance to HTLV-1-infected T cells via suppression of Bid and Bim expression

  2014cited by this paper
• Protons and more: state of the art in radiotherapy

  2014cited by this paper
• Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs.

  2014cited by this paper
• Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors

  2014cited by this paper
• Histone Deacetylation Critically Determines T Cell Subset Radiosensitivity

  2014cited by this paper
• Loss of Bak enhances lymphocytosis but does not ameliorate thrombocytopaenia in BCL-2 transgenic mice

  2014cited by this paper
• Genome engineering via TALENs and CRISPR/Cas9 systems: challenges and perspectives.

  2014cited by this paper
• Protons and more: state of the art in radiotherapy.

  2014cited by this paper
• TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity

  2014cited by this paper
• PI3K and Bcl-2 Inhibition Primes Glioblastoma Cells to Apoptosis through Downregulation of Mcl-1 and Phospho-BAD

  2014cited by this paper
• Easy quantitative assessment of genome editing by sequence trace decomposition

  2014cited by this paper
• Design and development of therapies using chimeric antigen receptor‐expressing T cells

  2014cited by this paper
• Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9.

  2014cited by this paper
• High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity

  2013cited by this paper
• Current concepts in clinical radiation oncology

  2013cited by this paper
• The basic principles of chimeric antigen receptor design.

  2013cited by this paper
• ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering.

  2013cited by this paper
• Highly Efficient Targeted Mutagenesis of Drosophila with the CRISPR/Cas9 System

  2013cited by this paper
• Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

  2013cited by this paper
• Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer

  2013cited by this paper
• DNA targeting specificity of RNA-guided Cas9 nucleases

  2013cited by this paper
• The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA

  2013cited by this paper
• TALEN or Cas9 - rapid, efficient and specific choices for genome modifications.

  2013cited by this paper
• Efficient In Vivo Genome Editing Using RNA-Guided Nucleases

  2013cited by this paper
• CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

  2013cited by this paper
• TALENs: a widely applicable technology for targeted genome editing

  2012cited by this paper
• Minor cell death defects but reduced tumor latency in mice lacking the BH3-only proteins Bad and Bmf

  2012cited by this paper
• Cell Function The TIGIT/CD226 Axis Regulates Human T

  2012cited by this paper
• CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.

  2012cited by this paper
• CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

  2012cited by this paper
• Combinatorial Immunotherapy

  2012cited by this paper
• T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy

  2012cited by this paper
• A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity

  2012cited by this paper
• The TIGIT/CD226 Axis Regulates Human T Cell Function

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• targeted gene knockout by direct delivery of zinc-finger nuclease proteins

  2012cited by this paper
• VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2

  2012cited by this paper
• Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

  2011cited by this paper
• Bid and Bim Collaborate during Induction of T Cell Death in Persistent Infection

  2011cited by this paper
• Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity

  2011cited by this paper
• Cyclic AMP-mediated immune regulation--overview of mechanisms of action in T cells.

  2011cited by this paper
• Multiple BH3 Mimetics Antagonize Antiapoptotic MCL1 Protein by Inducing the Endoplasmic Reticulum Stress Response and Up-regulating BH3-only Protein NOXA*

  2011cited by this paper
• Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions

  2011cited by this paper
• A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity

  2011cited by this paper
• TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.

  2010cited by this paper
• Quantification of zinc finger nuclease-associated toxicity.

  2010cited by this paper
• CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.

  2010cited by this paper
• High-resolution mapping of prostaglandin E2-dependent signaling networks identifies a constitutively active PKA signaling node in CD8+CD45RO+ T cells.

  2010cited by this paper
• A rapid and general assay for monitoring endogenous gene modification.

  2010cited by this paper
• Knockdown of human bid gene expression enhances survival of CD8+ T cells.

  2009cited by this paper
• In vitro induction of T cells that are resistant to A2 adenosine receptor‐mediated immunosuppression

  2009cited by this paper
• Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

  2009cited by this paper
• Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade.

  2009cited by this paper
• Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly.

  2009cited by this paper
• Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim.

  2009cited by this paper
• Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death.

  2009cited by this paper
• CD200: a putative therapeutic target in cancer.

  2008cited by this paper
• The inhibitory collagen receptor LAIR‐1 (CD305)

  2008cited by this paper
• Transcription factor FOXO3a controls the persistence of memory CD4+ T cells during HIV infection

  2008cited by this paper
• Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.

  2008cited by this paper
• Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways

  2008cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor

  2008cited by this paper
• Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates γ irradiation–induced thymic lymphoma development

  2008cited by this paper
• Gamma-secretase inhibitors reverse glucocorticoid resistance in T-ALL

  2008cited by this paper

• Improving CAR T cell therapy against malignancies through gene knock-down/out strategies: a systematic review

  2025cites this paper
• Current status of chimeric antigen receptor T cell therapy and its exhaustion mechanism.

  2025cites this paper
• Prospect of chimeric antigen receptor T-cell therapy for cancer

  2025cites this paper
• CAR-T cell therapy: a game-changer in cancer treatment and beyond

  2024cites this paper
• Strategies for Improving CAR T Cell Persistence in Solid Tumors

  2024cites this paper
• CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy

  2024cites this paper
• Significant Advancements and Evolutions in Chimeric Antigen Receptor Design

  2024cites this paper
• Revolutionizing cancer treatment: the emerging potential and potential challenges of in vivo self-processed CAR cell therapy

  2024cites this paper
• Oxidative stress induction by OCPs and OPPs pesticides may cause lung cancer incidence

  2023cites this paper
• Enhancement of cisplatin-induced apoptosis by saffron in human lung cancer cells.

  2023cites this paper
• Engineering CAR T cells for enhanced efficacy and safety

  2022cites this paper
• Oxidative Stress Induction By Pesticides May Cause Lung Cancer Incidence

  2022cites this paper
• Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future

  2022cites this paper
• Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy

  2021cites this paper
• Commentary - CRISPR-based techniques: Cas9, Cas13 and their applications in the era of COVID-19.

  2021cites this paper
• Envisioning the immune system to determine its role in pancreatic ductal adenocarcinoma: culprit or victim?

  2021cites this paper
• In silico prediction of B and T cell epitopes based on NDV fusion protein for vaccine development against Newcastle disease virus

  2021cites this paper
• Evaluation of the Effect of Crocin on Doxorubicin-Induced Cardiotoxicity.

  2021cites this paper
• Targeting cancer cells: from historic methods to modern chimeric antigen receptor (CAR) T-Cell strategies

  2020cites this paper
• Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity

  2020cites this paper
• Biomarkers for predicting the outcome of various cancer immunotherapies.

  2020cites this paper
• A metabolic switch to memory CAR T cells: Implications for cancer treatment.

  2020cites this paper
• Comparative Studies on the Chemo and Biosynthesized Nanomaterials for the Remediation of Pharmaceutical Residues in Wastewater

  2020cites this paper
• Comprehensive assessment of PD-L1 and PD-L2 dysregulation in gastrointestinal cancers.

  2020cites this paper
• Chemical synthesis and characterization of zinc, iron and carbon-based nanoparticles and their nanocomposites

  2020cites this paper
• CAR-T cells: Early successes in blood cancer and challenges in solid tumors

  2020cites this paper
• Sequential treatment with aT19 cells generates memory CAR-T cells and prolongs the lifespan of Raji-B-NDG mice.

  2020cites this paper
• Chimeric Antigen Receptor-Engineered T-Cells - a New Way and Era for Lymphoma Treatment.

  2020cites this paper
• Cancer stem cells and oral cancer: insights into molecular mechanisms and therapeutic approaches

  2020cites this paper
• Cancer stem cells and combination therapies to eradicate them.

  2020cites this paper
• CRISPR as a tool in tumor therapy: A short review

  2020cites this paper
• Advances in improving CAR-T cell exhaustion in cancer immunotherapy

  2020cites this paper
• CAR T cell therapy: newer approaches to counter resistance and cost

  2020cites this paper
• Gene modification strategies for next-generation CAR T cells against solid cancers

  2020influential citation
• Advance genome editing technologies in the treatment of human diseases: CRISPR therapy (Review)

  2020cites this paper
• CAR T-cell immunotherapy of B-cell malignancy: the story so far

  2020cites this paper
• Expression profile of stem cell markers and ABC transporters in 5-fluorouracil resistant Hep-2 cells

  2020cites this paper
• 造血干细胞移植后复发急性B淋巴细胞白血病CD19 CAR-T细胞治疗后的维持治疗

  2020cites this paper
• Vitamin D and non-coding RNAs: new insights into the regulation of breast cancer.

  2020cites this paper
• A brief review concerning Chimeric Antigen Receptors T cell therapy

  2020cites this paper
• Cervical Cancer Diagnosis: Insights into Biochemical Biomarkers and Imaging techniques.

  2020cites this paper
• Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant

  2020cites this paper
• Bacteriocins: New Potential Therapeutic Candidates in Cancer Therapy.

  2020cites this paper
• Immunotherapy in pancreatic cancer: New hope or mission impossible?

  2019cites this paper
• Cancer stem cells as therapeutic targets of pancreatic cancer

  2019cites this paper
• CAR T cell therapy: A new era for cancer treatment (Review).

  2019cites this paper
• Circulating microRNAs as potential diagnostic biomarkers and therapeutic targets in prostate cancer: Current status and future perspectives

  2019cites this paper
• Leukemia‐derived exosomes: Bringing oncogenic signals to blood cells

  2019cites this paper
• MicroRNAs and response to therapy in leukemia

  2019cites this paper
• Knockdown of Sal‐like 4 expression by siRNA induces apoptosis in colorectal cancer

  2019cites this paper
• MicroRNA and exosome: Key players in rheumatoid arthritis

  2019cites this paper
• Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors

  2019cites this paper
• Construction and functional characterization of a fully human anti‐CD19 chimeric antigen receptor (huCAR)‐expressing primary human T cells

  2018cites this paper
• Chimeric antigen receptor modified T-cells for cancer treatment

  2018cites this paper
• Knockdown of sal‐like 4 expression by small interfering RNA induces apoptosis in breast cancer cells

  2018cites this paper
• Vaccines for colorectal cancer: an update

  2018cites this paper
• Predictive and therapeutic biomarkers in chimeric antigen receptor T‐cell therapy: A clinical perspective

  2018cites this paper